Payment overview · 2025
General Payments
$554.58
24 reported records · 10 companies
Healthcare provider profile · identity verified
Alejandro Cordero, MD
Allopathic & Osteopathic Physicians|Internal Medicine · MIAMI, FL · NPI 1083695613
Verified facts
What the public records show
CMS Open Payments records show Alejandro Cordero, MD received $554.58 in general payments during 2025 across 24 reported records.
Amgen Inc. accounted for 16.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Ozempic, Paxlovid, Prolia.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Prolia by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 97 claims for Farxiga by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 363 claims for Eliquis by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 363 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $93.71 | 16.9% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $81.46 | 14.7% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $70.41 | 12.7% | 3 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $56.29 | 10.2% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $53.69 | 9.7% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $52.44 | 9.5% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $52.10 | 9.4% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $44.72 | 8.1% | 3 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $25.46 | 4.6% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $24.30 | 4.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $554.58 | 24 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $81.46 | 4 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $70.41 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $66.79 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $63.33 | 3 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $56.29 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $53.69 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $52.10 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $49.43 | 2 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $49.43 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $44.72 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $44.28 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $44.28 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $25.00 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $24.30 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 363 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 97 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 69 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 27 | exact normalized | Medicare Part D |
| PROLIA prolia |
2025 | Prolia | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
97 | 24 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
363 | 55 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
69 | 12 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
363 | 55 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
27 | 27 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 570 | 168 |
| Atorvastatin Calcium | Atorvastatin Calcium | 564 | 160 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 551 | 191 |
| Levothyroxine Sodium | Levothyroxine Sodium | 550 | 126 |
| Metformin Hcl | Metformin Hcl | 369 | 103 |
| Escitalopram Oxalate | Escitalopram Oxalate | 366 | 86 |
| Eliquis | Apixaban | 363 | 55 |
| Losartan Potassium | Losartan Potassium | 347 | 92 |
| Gabapentin | Gabapentin | 341 | 82 |
| Famotidine | Famotidine | 278 | 83 |
| Metoprolol Succinate | Metoprolol Succinate | 262 | 84 |
| Alprazolam | Alprazolam | 261 | 65 |
| Omeprazole | Omeprazole | 245 | 76 |
| Metoprolol Tartrate | Metoprolol Tartrate | 229 | 55 |
| Temazepam | Temazepam | 223 | 35 |
| Pantoprazole Sodium | Pantoprazole Sodium | 205 | 65 |
| Lisinopril | Lisinopril | 200 | 63 |
| Trazodone Hcl | Trazodone Hcl | 192 | 39 |
| Furosemide | Furosemide | 180 | 53 |
| Tamsulosin Hcl | Tamsulosin Hcl | 173 | 42 |
| Clopidogrel | Clopidogrel Bisulfate | 167 | 42 |
| Memantine Hcl | Memantine Hcl | 157 | 28 |
| Azithromycin | Azithromycin | 142 | 117 |
| Montelukast Sodium | Montelukast Sodium | 128 | 30 |
| Mounjaro | Tirzepatide | 123 | 20 |
| Carvedilol | Carvedilol | 118 | 37 |
| Glimepiride | Glimepiride | 117 | 33 |
| Januvia | Sitagliptin Phosphate | 117 | 22 |
| Simvastatin | Simvastatin | 114 | 28 |
| Fluticasone Propionate | Fluticasone Propionate | 113 | 55 |
| Ezetimibe | Ezetimibe | 112 | 30 |
| Valsartan | Valsartan | 104 | 26 |
| Allopurinol | Allopurinol | 100 | 25 |
| Meloxicam | Meloxicam | 98 | 48 |
| Potassium Chloride | Potassium Chloride | 98 | 28 |
| Farxiga | Dapagliflozin Propanediol | 97 | 24 |
| Hydralazine Hcl | Hydralazine Hcl | 97 | 39 |
| Atenolol | Atenolol | 94 | 21 |
| Donepezil Hcl | Donepezil Hcl | 94 | 21 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 94 | 23 |
| Pioglitazone Hcl | Pioglitazone Hcl | 92 | 31 |
| Irbesartan | Irbesartan | 91 | 20 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 88 | 45 |
| Mupirocin | Mupirocin | 87 | 30 |
| Pravastatin Sodium | Pravastatin Sodium | 86 | 24 |
| Hydrochlorothiazide | Hydrochlorothiazide | 84 | 26 |
| Clonazepam | Clonazepam | 81 | 24 |
| Quetiapine Fumarate | Quetiapine Fumarate | 79 | 22 |
| Sertraline Hcl | Sertraline Hcl | 78 | 25 |
| Ssd | Silver Sulfadiazine | 76 | 35 |
| Jardiance | Empagliflozin | 75 | 21 |
| Xarelto | Rivaroxaban | 75 | 18 |
| Folic Acid | Folic Acid | 72 | 17 |
| Dicyclomine Hcl | Dicyclomine Hcl | 70 | 32 |
| Ipratropium Bromide | Ipratropium Bromide | 69 | 11 |
| Ozempic | Semaglutide | 69 | 12 |
| Azelastine Hcl | Azelastine Hcl | 68 | 43 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 67 | 24 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 65 | suppressed |
| Telmisartan | Telmisartan | 63 | 21 |
| Duloxetine Hcl | Duloxetine Hcl | 61 | 13 |
| Methocarbamol | Methocarbamol | 59 | 47 |
| Mirtazapine | Mirtazapine | 59 | 20 |
| Tramadol Hcl | Tramadol Hcl | 59 | 25 |
| Alendronate Sodium | Alendronate Sodium | 58 | 18 |
| Buspirone Hcl | Buspirone Hcl | 58 | 17 |
| Finasteride | Finasteride | 57 | 16 |
| Synthroid | Levothyroxine Sodium | 57 | 16 |
| Fenofibrate | Fenofibrate | 56 | 22 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 56 | 20 |
| Clonidine Hcl | Clonidine Hcl | 55 | 23 |
| Meclizine Hcl | Meclizine Hcl | 53 | 21 |
| Bumetanide | Bumetanide | 52 | 19 |
| Pregabalin | Pregabalin | 52 | 14 |
| Bupropion Xl | Bupropion Hcl | 50 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 50 | 17 |
| Megestrol Acetate | Megestrol Acetate | 50 | 18 |
| Entresto | Sacubitril/Valsartan | 47 | suppressed |
| Latanoprost | Latanoprost | 47 | suppressed |
| Lorazepam | Lorazepam | 46 | suppressed |
| Novolog Flexpen | Insulin Aspart | 46 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 46 | 28 |
| Zolpidem Tartrate | Zolpidem Tartrate | 45 | suppressed |
| Nystatin | Nystatin | 43 | 18 |
| Humalog Kwikpen U-100 | Insulin Lispro | 42 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 41 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 40 | 33 |
| Baclofen | Baclofen | 40 | suppressed |
| Celecoxib | Celecoxib | 39 | 21 |
| Spironolactone | Spironolactone | 39 | 12 |
| Diclofenac Sodium | Diclofenac Sodium | 38 | 21 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 38 | 30 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 37 | 11 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 37 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 37 | 12 |
| Myrbetriq | Mirabegron | 37 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 37 | 20 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 36 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 36 | 14 |
| Metformin Hcl Er | Metformin Hcl | 36 | 13 |
| Ondansetron Hcl | Ondansetron Hcl | 36 | 17 |
| Levofloxacin | Levofloxacin | 35 | 19 |
| Methylprednisolone | Methylprednisolone | 35 | 31 |
| Nebivolol Hcl | Nebivolol Hcl | 35 | 12 |
| Clobetasol Propionate | Clobetasol Propionate | 34 | 25 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 34 | 18 |
| Nifedipine Er | Nifedipine | 34 | 11 |
| Prednisone | Prednisone | 34 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 33 | suppressed |
| Ketoconazole | Ketoconazole | 33 | 19 |
| Ondansetron Odt | Ondansetron | 33 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 33 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 32 | suppressed |
| Hydrocortisone | Hydrocortisone | 32 | 20 |
| Fluoxetine Hcl | Fluoxetine Hcl | 31 | suppressed |
| Glipizide | Glipizide | 31 | suppressed |
| Nystop | Nystatin | 30 | 17 |
| Tradjenta | Linagliptin | 30 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 29 | suppressed |
| Linzess | Linaclotide | 28 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 27 | suppressed |
| Lidocaine | Lidocaine | 27 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 27 | 27 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 27 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 27 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 26 | suppressed |
| Alogliptin | Alogliptin Benzoate | 25 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 25 | suppressed |
| Vascepa | Icosapent Ethyl | 25 | suppressed |
| Timolol Maleate | Timolol Maleate | 24 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 24 | suppressed |
| Budesonide | Budesonide | 23 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 23 | 21 |
| Glipizide Er | Glipizide | 23 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 23 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 23 | suppressed |
| Sucralfate | Sucralfate | 23 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 22 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 22 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 22 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 21 | suppressed |
| Cholestyramine Light | Cholestyramine | 20 | suppressed |
| Clonidine | Clonidine | 20 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 20 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 20 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 20 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 19 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 19 | suppressed |
| Creon | Lipase/Protease/Amylase | 19 | 11 |
| Doxazosin Mesylate | Doxazosin Mesylate | 19 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 19 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 19 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 19 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 18 | 15 |
| Anastrozole | Anastrozole | 18 | suppressed |
| Digoxin | Digoxin | 18 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 18 | suppressed |
| Calcitriol | Calcitriol | 17 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 16 | 12 |
| Eszopiclone | Eszopiclone | 16 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 16 | suppressed |
| Olanzapine | Olanzapine | 16 | suppressed |
| Prolia | Denosumab | 16 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 16 | suppressed |
| Fluconazole | Fluconazole | 15 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 15 | 15 |
| Ramipril | Ramipril | 15 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 15 | 11 |
| Ciclopirox | Ciclopirox | 14 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 14 | suppressed |
| Lactulose | Lactulose | 14 | 11 |
| Lovastatin | Lovastatin | 14 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 14 | suppressed |
| Rivastigmine | Rivastigmine | 14 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 13 | suppressed |
| Novolog | Insulin Aspart | 13 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 13 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 13 | suppressed |
| Atropine Sulfate | Atropine Sulfate | 12 | suppressed |
| Belsomra | Suvorexant | 12 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 12 | suppressed |
| Diazepam | Diazepam | 12 | suppressed |
| Ibuprofen | Ibuprofen | 12 | suppressed |
| Indapamide | Indapamide | 12 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Livalo | Pitavastatin Calcium | 12 | suppressed |
| Metronidazole | Metronidazole | 12 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 12 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 12 | suppressed |
| Trulicity | Dulaglutide | 12 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 11 | suppressed |
| Aripiprazole | Aripiprazole | 11 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 11 | suppressed |
| Cefadroxil | Cefadroxil | 11 | suppressed |
| Cefdinir | Cefdinir | 11 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 11 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 11 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 11 | suppressed |
| Scopolamine | Scopolamine | 11 | suppressed |
| Tobramycin | Tobramycin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $554.58 · 24 records | Amgen Inc. | ELIQUIS, EVENITY, FARXIGA, FREESTYLE LIBRE 3, GEMTESA, NURTEC ODT, OTEZLA, Ozempic, PAXLOVID, PROLIA, REPATHA, The Cologuard Plus Collection Kit, Veozah, WATCHMAN FLX | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error